10006856

# 07/06/2005 WABDELR1 00000050 081641

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	) Examiner: McKelvey, Terry Alan
	)
Kevin P. BAKER, et al.	) Art Unit: 1636
Application Serial No. 10/006,856	) Confirmation No: 8365
Filed: December 6, 2001	) Attorney's Docket No. 39780-2830 P1C14
For: SECRETED AND	Customer No. 35489
TRANSMEMBRANE	)
POLYPEPTIDES AND NUCLEIC	)
ACIDS ENCODING THE SAME	

EXPRESS MAIL LABEL NO.: EL 976 545 064 US

DATE MAILED: JUNE 29, 2005

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT **UNDER 37 C.F.R. §1.97**

### MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):					
	(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  OR			
	(2)	It is being filed within 3 months of entry of a national stage OR			
	(3)	It is being filed before the mail date of the first Office Action on the merits			

	OR  (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.	
filing of stage a action	F.R. $\S1.97(c)$ . If this statement is being filed after the latest of: (1) three months beyond the date of a national application; (2) three months beyond the date of entry of the national as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office on the merits, but before the mailing date of the earlier of a final office action under $\S1.113$ otice of allowance under $\S1.311$ , then:	
	a certification as specified in §1.97(e) is provided below; or	
$\boxtimes$	a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.	
37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier office action under §1.113 or a notice of allowance under §1.311, but before payment fee, then:		
A.	a certification as specified in §1.97(e) is completed below; and	
B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and	

the payment of other papers filed together with this statement.

Respectfully submitted,

a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with

Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees

communication to Deposit Account No. <u>08-1641 (Attorney's Docket No. 39780-2830 P1C14)</u>.

of \$180.00 and charge any additional fees or credit any overpayment associated with this

Dated: June 28, 2005

C.

 $\boxtimes$ 

By: Barrie D. Greene (Reg. No. 46,740)

HELLER EHRMAN WHITE & McAULIFFE LLP

275 Middlefield Road Menlo Park, CA 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

SV 2131171 v1 (39780.2830)

Form PTO-1449 SUPPLEMENTAL			<del>-</del>	Attorney's Docket No. 39780-2830 P1C14	,	Application Serial No. 10/006,856			
INFORMATION DISCLOSURE STATEMENT			10/	10/000,030					
		DISCE			in P. BAKER,	et al.			
	. <u>-</u> .,			Filing Date:	<u> </u>	oup Art Uni	t:		
	(use sev	eral sheet.	s if necessary)	December 6, 2001	163	-		-	
			The second secon	PATENT DOCUMENTS					
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Filing Dat	e	
Initials	No.						(if approp	riate)	
			FOREI	SN PATENT DOCUMENTS					
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Translation		
Initials	No.	<u> </u>					YES	NO	
				THER DOCUMENTS thor, title, date, pertinent pages,	etc.)				
Examiner	Ref.	Title				<u> </u>			
Initials	No.								
	1.			nic Acid $\gamma$ -Monohydroxamate", $\gamma$	The Journal of B	iomedical C	hemistry, Vo	ol. 274,	
		4	p 26617-26624, September						
	2.	Hanna, J.S., et al., "HER-2/neu Breat Cancer Predictive Testing", Oathology Associates Medical Laboratores - (1999).							
	3.	Hyman, I	E., et al., "Impact of DNA	Amplification on Gene Expression	on Patterns in Br	east Cancer	,2", Cancer		
		Research – <u>62</u> :6240-6245 (2002).							
	4.	Mueller, Wendy M., et al., "Evidence That Glucose Metabolism Regulates Leptin Secretion from Cultured Rat							
	5.	Adipocytes", Endocrinology, Vol. 139, No. 2, pp 551-558 (1998).							
	J.	Mueller, Wendy M., et al., "Effects of Metformin and Vanadium on Leptin Secretion from Cultured Rat Adipocytes", Obesity Research, Vol. 8, No. 7, pp 530-539, October 2000.							
	6.	<del></del>		Study of Gene Copy Numbers, 7		Protein I eve	ls in Pairs of	f Non-	
	0.								
	7.	Invasive and Invasive Human Transitional Cell Carcinomas", <i>Molecular &amp; Cellular Proteomics</i> - 1:37-45 (2002).  Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the							
				Breast Tumors", PNAS - 99(20)	the Care of several description of the United Section	and the second s			
	8.	Sandouk, Tagrid, et al., "The Antidiabetic Agent Pioglitazone Increases Expression of Glucose Transporters in 3T3-							
				ger Ribonucleic Acid Transcript S	Stability", Endoc	rinology, V	ol. 133, No.	1, pp	
	0	352-359 (	<u> </u>	1 D'CC (' ' D 1 C1	<b>*</b> * * * * * * * * * * * * * * * * * *	1.01			
	9.	Tafuri, Sherrie R., "Troglitazone Enhances Differentiation, Basal Glucose Uptake, and Glut 1 Protein Levels in 3T3-L1 Adipocytes", Endocrinology, Vol. 137, No. 11, pp 4706-4712 (1996).							
		313-L1 F	Adipocytes, Endocrinolog	y, voi. 157, No. 11, pp 4700-471	2 (1990).	<del></del>	<del></del>		
		<del> </del>				· <del>-</del> ··,			
		-	<del></del>				<del></del>	·	
				· , , , , , , , , , , , , , , , , , , ,	······································				
							<u> </u>		

EXAMINER:		DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2131171 v1